Trial Profile

A phase 3 study of CBL-514

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CBL-514 (Primary)
Indications Adiposis dolorosa; Cellulite; Obesity
Focus Registrational; Therapeutic Use

Most Recent Events

12 Mar 2025 According to Caliway Biopharmaceuticals media release, subject recruitment expected in Q3 2025.
23 Jan 2024 According to a Caliway Biopharmaceuticals media release, company will submit the final Pivotal Phase 3 study protocol as soon as the preliminary result of the CBL-0204 Phase 2b study is announced.
23 Jan 2024 According to a Caliway Biopharmaceuticals media release, announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com